Tracking In Situ Checkpoint Inhibitor-Bound Target T Cells Academic Background Checkpoint inhibitors (CPIs) have revolutionized cancer treatment by blocking immune regulatory signals mediated by checkpoint molecules, restoring T cell-mediated tumor clearance. However, these therapies also lead to a range of immune-related adverse events (IRAEs), wi...